A 28-year-old woman from Mumbai is found to be HIV-positive on routine screening. She is asymptomatic with a CD4+ count of 450 cells/μL. To assess her current viral replication status and guide antiretroviral therapy initiation, which investigation is most appropriate?

Explanation

## Investigation of Choice for Assessing Viral Replication in Established HIV Infection ### Clinical Context This patient has confirmed HIV infection (positive screening) and is asymptomatic with a CD4+ count of 450 cells/μL. The question asks for the investigation that **quantifies current viral replication** and guides treatment decisions. ### Why HIV RNA Viral Load (RT-PCR) is the Best Answer **Key Point:** **HIV RNA viral load by RT-PCR is the gold standard for assessing viral replication burden** and is essential for: 1. Determining the need for antiretroviral therapy (ART) 2. Monitoring treatment response 3. Detecting virological failure 4. Guiding clinical management **High-Yield:** Viral load is the **strongest predictor of disease progression** — more predictive than CD4+ count alone. It directly quantifies the number of HIV RNA copies per milliliter of plasma. ### Role of Investigations in HIV Management | Investigation | Purpose | Timing | |---|---|---| | **HIV RNA (Viral Load)** | **Quantify replication; guide ART** | At diagnosis, before ART, during treatment | | **CD4+ count** | Assess immunosuppression; guide prophylaxis | At diagnosis, every 3–6 months | | **Genotyping** | Detect resistance mutations | Before ART initiation (baseline); if virological failure | | **p24 antigen** | Diagnostic marker (not quantitative) | Not routinely used for monitoring | | **Antibody ELISA** | Diagnostic confirmation | At diagnosis only | **Clinical Pearl:** In this patient: - CD4+ count of 450 cells/μL indicates moderate immunosuppression (ART threshold is typically ≤500 in India per NACO guidelines, though WHO now recommends ART for all) - **Viral load will determine urgency of ART initiation** — high viral load (>100,000 copies/mL) indicates rapid replication and need for immediate ART - Viral load is also the **best marker of treatment response** — undetectable viral load (<50 copies/mL) indicates successful ART ### Why Other Options Are Incorrect **Genotyping (Option A):** While genotyping is important, it is typically done **after baseline viral load assessment** or if virological failure occurs. It is not the first investigation for assessing current replication status. **Repeat HIV Antibody ELISA (Option C):** Once HIV is confirmed, repeat serology is not indicated. Antibodies remain positive lifelong regardless of viral load or CD4+ count. **p24 Antigen (Option D):** p24 is a diagnostic marker used in acute infection, not for quantifying viral replication or monitoring established infection. It is not routinely measured in asymptomatic patients. ### Current NACO/WHO Algorithm for Newly Diagnosed HIV ```mermaid flowchart TD A["Confirmed HIV diagnosis"]:::outcome --> B["Measure CD4+ count & Viral Load"]:::action B --> C{"CD4+ < 500 or VL > threshold?"}:::decision C -->|Yes| D["Initiate ART immediately"]:::action C -->|No| E["Monitor CD4 & VL every 3-6 months"]:::action D --> F["Baseline genotyping (if resources available)"]:::action F --> G["Start first-line ART"]:::action G --> H["Repeat VL at 12 weeks to assess response"]:::action ``` **Key Point:** Viral load is the **primary driver of treatment decisions** in newly diagnosed HIV patients. It must be measured at baseline before ART initiation.